linjc16/ctgov huggingface dataset:
Impact of Information About Booster Vaccination Against DTPolio at 25 Years on This Booster Vaccination's Realization

Study Overview
=================
Brief Summary
-----------------
The aim of vaccination is to protect the patient against disease by stimulating his immune system. DTPolio is a tetravalent vaccine providing protection against pertussis, diphtheria, tetanus and polio. In France, the vaccination schedule sets the vaccination recommendations applicable to people according to their age. In this schedule, a booster of DTPolio at the age of 25 is recommended. The vaccination coverage for patients over 16 years of age is insufficient in France.

Detailed Description
-----------------
The aim of the study is to evaluate impact of information about booster vaccination against DTPolio at 25 years on this booster vaccination's realization.

Official Title
-----------------
Impact of Information About Booster Vaccination Against DTPolio at 25 Years on This Booster Vaccination's Realization

Conditions
-----------------
Vaccination

Intervention / Treatment
-----------------
* Other: Data collection: DTPolio vaccine delivery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: aged 25 years old in 2020 without delivery of DTPolio vaccine in 2019 or 2020 Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 25 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| With information about booster vaccination<br>Adults aged 25 years in 2020 without delivery of DTPolio vaccine in 2019 or 2020, to whom information concerning this vaccination is given | Other: Data collection: DTPolio vaccine delivery<br>* with information about booster vaccination group: Sending of information concerning booster vaccination against DTPolio at 25 years using letters, emails and SMS without information about booster vaccination group: no intervention<br>|
| Without information about booster vaccination<br>Adults aged 25 years in 2020 without delivery of DTPolio vaccine in 2019 or 2020, to whom information concerning this vaccination is not given. | Other: Data collection: DTPolio vaccine delivery<br>* with information about booster vaccination group: Sending of information concerning booster vaccination against DTPolio at 25 years using letters, emails and SMS without information about booster vaccination group: no intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| DTPolio vaccine delivery | DTPolio vaccine delivery by pharmacies within 12 months of sending information about booster vaccination against DTPolio at 25 years | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Booster vaccination, Adult, Information, DTPolio
The Treatment of Carpal Tunnel Syndrome Using Thumb Pressure Along the Median Nerve

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to find the efficacy of treating the muscles in the inside (biceps,pronator teres) of the arm in order to eliminate the carpal tunnel syndrome .The authors hypothesise that eliminating the trigger points located in these muscles would diminish the symptoms associated with the carpal tunnel syndrome.

Detailed Description
-----------------
The carpal tunnel syndrome is a common condition which should treated by surgery only when conservative approaches has been tried.In the present trial the authors intend to find the effectiveness of treating the triggers points located in the biceps muscle, the pronator teres muscle and the biceps aponeurosis on the symptoms normally associated with the carpal tunnel syndrome. The technique used in this trial will be ischemic compression(thumb tip pressure)on the trigger points located on the previous sites.

Official Title
-----------------
Neuropathy Along the Median Nerve: Etiology of Symptoms Associated With the Carpal Tunnel Syndrome: a Preliminary Study.

Conditions
-----------------
Carpal Tunnel Syndrome

Intervention / Treatment
-----------------
* Procedure: Active Comparator, ischemic compressions


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults between 20 and 60 years old from the city and the surrounding Trois-Rivières with chronic carpal tunnel syndrome, Daily pain in the hand that lasted at least 3 months Exclusion Criteria: History of upper limb or neck surgery, Pregnancy and systemic pathologies possibly related to carpal tunnel syndrome, such as hypothyroidism, diabetes and rheumatoid arthritis.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: One<br>Ischemic Compression on Triggers Points on Muscles along the Median Nerve. Active Comparator | Procedure: Active Comparator, ischemic compressions<br>* Ischemic Compressions,3 times a week,5 weeks.<br>* Other names: Pressure Point Therapy;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain,functional disabilities |  | One year |
Influence of Two Different Preloaded Intraocular Lens (IOLs) on Posterior Capsule Opacification

Study Overview
=================
Brief Summary
-----------------
Studies showed that a sharp posterior optic edge of an intraocular lens (IOL) inhibits migration of lens epithelial cells in between posterior capsule and optic of the IOL and therefore reduces the rate of posterior capsule opacification (PCO). In present time most IOLs implanted have a sharp posterior optic edge. Due to differences in IOL production different IOLs have different rates of PCO. Progression in cataract surgery technique allow phacoemulsification through micro-incisions. Therefore there is need for IOLs that can be implanted through incisions of about 2.5 mm. This study investigates the effect of two different hydrophobic acrylic IOLs with a sharp posterior optic edge on the rate of PCO after implantation through a micro-incision. The results will be compared intraindividually.

Detailed Description
-----------------
prospective, randomized, bilateral study with intraindividual comparison, implantation of a Polylens Y10 IOL in one eye and implantation of a Polylens Y30 in the contralateral eye. PCO rate will be detected at 1 year and 2 years.

Official Title
-----------------
Influence of Two Sharp-edged Hydrophobic Acrylic Micro-incision-IOLs on Posterior Capsule Opacification. A Randomized, Double-masked Study With Intraindividual Comparison.

Conditions
-----------------
Cataract

Intervention / Treatment
-----------------
* Procedure: cataract surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: bilateral age-related cataract age 55 to 80 years expected postoperative visual acuity of at least 0.5 Exclusion Criteria: amblyopia corneal scars diabetes pseudoexfoliation-syndrome earlier ocular surgeries or laser treatments intraocular tumors

Ages Eligible for Study
-----------------
Minimum Age: 55 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: A<br>cataract surgery, implantation of a Polylens Y10 | Procedure: cataract surgery<br>* cataract surgery with implantation of an IOL<br>* Other names: Polylens Y10 IOL, Polytech, Germany;|
| Other: B<br>cataract surgery, implantation of a Polylens Y30 | Procedure: cataract surgery<br>* cataract surgery with implantation of an IOL<br>* Other names: Polylens Y10 IOL, Polytech, Germany;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PCO rate |  | 2 years after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
posterior capsule opacification, micro incision, sharp optic edge
Platelet-Inhibitor Drug Trial in Coronary Angioplasty

Study Overview
=================
Brief Summary
-----------------
To determine the effectiveness of dipyridamole and aspirin in prevention of restenosis of the dilated lesion in patients who had undergone percutaneous transluminal coronary angioplasty (PTCA). Secondary aims were to determine the effectiveness of platelet inhibitor therapy in reducing the incidence of coronary events and the severity and incidence of angina.

Detailed Description
-----------------
BACKGROUND: By dilating coronary stenoses, PTCA can relieve angina pectoris and improve exercise tolerance and left ventricular function. However, restenosis occurs in 20-30 percent of dilated stenoses within three to six months following PTCA making it necessary to restrict patient activities, resume antianginal medications, repeat PTCA, or perform coronary artery bypass surgery. Balloon dilatation of the atherosclerotic lesion damages the endothelium, intima, and media of the artery. This may lead to restenosis via platelet deposition, mural thrombus formation, and intimal proliferation by mechanisms that appear similar to those causing aortocoronary vein graft (ACVG) occlusions. It had been demonstrated that dipyridamole plus aspirin therapy suppressed these mechanisms of ACVG occlusion in the animal model, prolonged a shortened platelet survival in patients with coronary artery disease, and reduced ACVG occlusions in patients both early and late after the operation. Thus, a trial of these drugs in patients undergoing PTCA was a logical and necessary step to reduce the major shortcoming of the initially successful PTCA therapy, namely the high rate of restenosis. DESIGN NARRATIVE: Randomized, double-blind, fixed sample. Patients were randomized to treatment with dipyridamole plus aspirin or placebo. The study completion date listed in this record was obtained from the Query/View/Report (QVR) System.

Conditions
-----------------
Angina Pectoris, Cardiovascular Diseases, Coronary Disease, Heart Diseases, Myocardial Ischemia

Intervention / Treatment
-----------------
* Drug: aspirin
* Drug: dipyridamole
* Procedure: angioplasty, transluminal, percutaneous coronary


Participation Criteria
=================
Eligibility Criteria
-----------------
Patients to age 80 with angina pectoris.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: aspirin|nan|
|Drug: dipyridamole|nan|
|Procedure: angioplasty, transluminal, percutaneous coronary|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to explore the changes in metabolic parameters in patients treated with escitalopram for six months for major depression, generalized anxiety disorder or panic disorder, with or without agoraphobia.

Detailed Description
-----------------
This is an open-label study, with 4 scheduled visits. Recruitment of 100 subjects. Assessments include demographics, diagnosis, smoking frequency, Clinical Global Scale (CGI-S), weight, height,blood pressure, waist and hip circumference and fasting blood glucose and lipd profile. Statistical analysis will be exploratory and mainly descriptive.

Official Title
-----------------
Open-label Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months

Conditions
-----------------
Major Depression, Generalized Anxiety Disorder, Panic Disorder

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Give informed consent Requires pharmacological treatment with escitalopram for major depression, generalized anxiety disorder or panic disorder Aged 21 years old and above Able to comprehend and comply with protocol Not pregnant and if of child-bearing age, using adequate methods of contraception Exclusion Criteria: Currently taking or has taken in previous 3 months, any other antidepressants, antipsychotics, mood stabilizers, weight loss or lipid-profile modifying drugs Contraindications to escitalopram Unstable medical illness and/or is already under treatment of diabetes, hypertension, dyslipidemia, ischemic heart disease History of non-response to escitalopram Meets IDF definition of metabolic syndrome Significant risk of suicide Primary diagnosis or comorbid diagnosis of psychotic disorder, bipolar disorder, substance dependence and/or dementia

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
metabolic parameters, escitalopram, metabolic syndrome, antidepressant
Ventilation's Parameters Applied in Emergency Medicine. A Prospective Observational Study

Study Overview
=================
Brief Summary
-----------------
To prospectively assess the mechanical ventilation management when its provided by Emergency Physicians in French Hospital, and to assess complications and outcome of these patients. The study could be measure the proportion of patients developing an Acute Respiratory Failure Distress after a take care of by French Emergency Departments.

Official Title
-----------------
Ventilation's Parameters Applied in Emergency Medicine. Observational Study

Conditions
-----------------
Mechanical Ventilation, Acute Respiratory Distress Syndrome, Protective Ventilation, Survival

Intervention / Treatment
-----------------
* Other: mechanical ventilation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age equal or over 18 years old Needing a invasive or noninvasive mechanical ventilation Mechanical ventilation initiated in Prehospital or IntraHospital Emergency Department by an Emergency Physician Exclusion Criteria: - Age under 18 years old

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: mechanical ventilation|All patients who need an invasive or non invasive mechanical ventilation, initiated in Prehospital or IntraHospital Emergency Department by an emergency Physician|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of patients benefiting of a early low-volume ventilation initiated Emergency Department or Prehospital Care. | Early Low volume ventilation will be defined according to a VtE < 8mL/lg | Day 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of patients benefiting of an early protective ventilation in Emergency Departments |  | Day 1 | 
| Proportion of patients with acute respiratory distress syndrome according to the Berlin Definition during the first eight days of following. | ARDS will be defined according to the Berlin definition. | from Day 1 to Day 8 and Day 28 | 
| Proportion of survival from day 1 to Day 8, and to day 28 |  | from Day 1 to Day 8 and Day 28 | 
| Indication to mechanical ventilation in Prehospital care and Emergency Departments |  | Day 1 | 
| Mechanical Ventilation Duration in Emergency Departments |  | Day 1 | 
| Mechanical ventilation settings in Emergency Departments | Recorded settings will be Ventilation mode, Tidal volume or Pressure Support Positive End Expiratory Pressure, Ventilation Rate, I : E ratio or Inspiratory Flow or Inspiratory Time. | Day 1 |
Analysis of the Curative Effect of Salvage Surgery on Recurrent Laryngeal Carcinoma

Study Overview
=================
Brief Summary
-----------------
Early laryngeal cancer can be treatment by laser surgery or radiotherapy, intermediate and advanced laryngeal carcinoma mainly surgical treatment. Laryngeal cancer is at risk of recurrence after treatment, whether in surgery, laser or radiotherapy. The recurrence rate of laryngeal cancer is about 10% reported at home and abroad. Local pain, ulcers, breathing and eating difficulties caused by recurrent laryngeal cancer seriously reduce the quality of life of patients and seriously endanger their lives. Therefore, head and neck surgeons are required to make every effort to give them saving treatment in order to improve their quality of life. Prolong the patient's life.

Detailed Description
-----------------
medical records and extracted information including age, gender, initial treatment modality of glottis cancer, recurrence time, recurrence site, histopathology, tumor grade according to World Health Organization (WHO) grade and tumor stage. Stages were defined according to the American Joint Committee on Cancer (AJCC) staging system.

Official Title
-----------------
Analysis of the Curative Effect of Salvage Surgery on Recurrent Laryngeal Carcinoma: A Single-institutional Experience

Conditions
-----------------
Recurrent Laryngeal Carcinoma

Intervention / Treatment
-----------------
* Procedure: salvage surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: more than 18 years, patients with recurrent glottic laryngeal squamous cell carcinoma undergoing salvage surgery Exclusion Criteria: postoperative radiotherapy and chemotherapy loss to follow-up

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: salvage surgery|Salvage surgery hopes to control the recurrence of larynx, pharynx, fistula and neck tumor and improve the quality of life and survival rate|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| overall survival (OS) | The overall survival rate was calculated with Kaplan-Meier method. | Follow up 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
salvage surgery, recurrent laryngeal carcinoma, experience
Comparison of CorWatch With Right Heart Catheter Measurements in Heart Failure

Study Overview
=================
Brief Summary
-----------------
This is an observational study to evaluate the agreement between the InCardia diagnostic technology CorWatch for the assessment of venous pressure in human subjects. This includes evaluation of InCardia technology in heart failure (HF) patients undergoing invasive right heart catheterization in a cardiac catheterization laboratory (cath lab) and in a cardiac intensive care unit (ICU).

Official Title
-----------------
Comparison of the InCardia Venous Pressure Diagnostic Technology CorWatch With Swan Ganz Catheter Measurements in the Cardiac Catheterization Laboratory and Cardiac Intensive Care Unit

Conditions
-----------------
Heart Failure

Intervention / Treatment
-----------------
* Diagnostic Test: CorWatch


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed with NYHA class II-IV heart failure irrespective of ejection fraction Patient is able to give consent Exclusion Criteria: Severe tricuspid regurgitation Mechanical ventilation Patient is pregnant Inability to access either of the patient's upper arms.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with heart failure undergoing right heart catheterization<br>Subjects with a diagnosis of NYHA class II-IV heart failure who meet the inclusion and exclusion criteria will be eligible for participation in this study. | Diagnostic Test: CorWatch<br>* Non-invasive wearable monitor for the assessment of central venous pressure<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Agreement with right atrial pressure as measured by Swan Ganz catheter | Agreement between the CVP/RAP as assessed by the CorWatchTM method and the right arterial pressure (RAP) as measured by SG catheter | During the right heart catheterization procedure | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
central venous pressure, right heart catheterization, hemodynamic congestion